

# Michael T Heneka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9573062/publications.pdf>

Version: 2024-02-01

242  
papers

33,439  
citations

5126

86  
h-index

4853

174  
g-index

260  
all docs

260  
docs citations

260  
times ranked

38811  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebral dysfunctions caused by sepsis during ageing. <i>Nature Reviews Immunology</i> , 2022, 22, 444-458.	10.6	55
2	p38 Inhibition Decreases Tau Toxicity in Microglia and Improves Their Phagocytic Function. <i>Molecular Neurobiology</i> , 2022, 59, 1632-1648.	1.9	6
3	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease. <i>Neuron</i> , 2022, 110, 1009-1022.e4.	3.8	27
4	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
5	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
6	Falls at advanced age – The importance to search for benign paroxysmal positional vertigo (BPPV). <i>Experimental Gerontology</i> , 2022, 165, 111868.	1.2	2
7	Interrelations of Alzheimer's disease candidate biomarkers neurogranin, fatty acid-binding protein 3 and ferritin to neurodegeneration and neuroinflammation. <i>Journal of Neurochemistry</i> , 2021, 157, 2210-2224.	2.1	15
8	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 614-628.	4.1	61
9	Vaccination with (11)E2 in alum efficiently induces an antibody response to A $\beta$ -amyloid without affecting brain A $\beta$ -amyloid load and microglia activation in 3xTg mice. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 1383-1387.	1.4	3
10	Major Surgery Affects Memory in Individuals with Cerebral Amyloid- $\beta$ Pathology. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 863-874.	1.2	9
11	mTOR-dependent translation amplifies microglia priming in aging mice. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	43
12	Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 626974.	1.7	15
13	Longitudinal Neurocognitive and Pulmonological Profile of Long COVID-19: Protocol for the COVIMMUNE-Clin Study. <i>JMIR Research Protocols</i> , 2021, 10, e30259.	0.5	8
14	Deletion of the inflammatory S100A9/MRP14 protein does not influence survival in hSOD1G93A ALS mice. <i>Neurobiology of Aging</i> , 2021, 101, 181-186.	1.5	2
15	Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1456-1470.	1.7	19
16	Systemic inflammation induced the delayed reduction of excitatory synapses in the CA3 during ageing. <i>Journal of Neurochemistry</i> , 2021, 159, 525-542.	2.1	25
17	Differential interaction with TREM2 modulates microglial uptake of modified A $\beta$ species. <i>Glia</i> , 2021, 69, 2917-2932.	2.5	9
18	In vivo mechanisms of cortical network dysfunction induced by systemic inflammation. <i>Brain, Behavior, and Immunity</i> , 2021, 96, 113-126.	2.0	12

#	ARTICLE	IF	CITATIONS
19	Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. <i>Cell</i> , 2021, 184, 5089-5106.e21.	13.5	158
20	SFRP1 modulates astrocyte-microglia crosstalk in acute and chronic neuroinflammation. <i>EMBO Reports</i> , 2021, 22, e51696.	2.0	27
21	Proteopathic tau primes and activates interleukin-1 $\beta$ via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathway. <i>Cell Reports</i> , 2021, 36, 109720.	2.9	42
22	Microglial NLRP3 Inflammasome Activation upon TLR2 and TLR5 Ligation by Distinct $\beta$ -Synuclein Assemblies. <i>Journal of Immunology</i> , 2021, 207, 2143-2154.	0.4	53
23	Peripheral and central immune system crosstalk in Alzheimer disease – a research prospectus. <i>Nature Reviews Neurology</i> , 2021, 17, 689-701.	4.9	169
24	Long-term exposure to fine particulate matter, lung function and cognitive performance: A prospective Dutch cohort study on the underlying routes. <i>Environmental Research</i> , 2021, 201, 111533.	3.7	16
25	Time course of dementia following sepsis in German health claims data. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	12
26	TREM2 modulates differential deposition of modified and non-modified A $\beta$ species in extracellular plaques and intraneuronal deposits. <i>Acta Neuropathologica Communications</i> , 2021, 9, 168.	2.4	12
27	A microRNA signature that correlates with cognition and is a target against cognitive decline. <i>EMBO Molecular Medicine</i> , 2021, 13, e13659.	3.3	29
28	Inflammasome activation in neurodegenerative diseases. <i>Essays in Biochemistry</i> , 2021, 65, 885-904.	2.1	23
29	Microglial PD $\beta$ 1 stimulation by astrocytic PD $\beta$ 1 suppresses neuroinflammation and Alzheimer's disease pathology. <i>EMBO Journal</i> , 2021, 40, e108662.	3.5	41
30	Teaching an old dog new tricks: serum troponin T as a biomarker in amyotrophic lateral sclerosis. <i>Brain Communications</i> , 2021, 3, fcab274.	1.5	10
31	Characterization of the NIA-AA Research Framework stage 2 in the longitudinal multicenter DELCODE study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
32	In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
33	Artificial neural network visualization methods reveal diagnostically relevant brain regions to detect Alzheimer's disease: The first step towards comprehensive artificial intelligence. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
34	Prediction of amyloid-positivity in individuals with subjective cognitive decline: Machine learning approaches to optimize number-needed-to-screen. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
35	CA3 excitatory synapse loss as a chronic effect of septic shock in middle-aged mice.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e052228.	0.4	0
36	Quantitative proteomics of synaptosome <i>S-nitrosylation</i> in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2020, 152, 710-726.	2.1	30

#	ARTICLE	IF	CITATIONS
37	A rare heterozygous <i>TREM2</i> coding variant identified in familial clustering of dementia affects an intrinsically disordered protein region and function of TREM2. <i>Human Mutation</i> , 2020, 41, 169-181.	1.1	4
38	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. <i>Alzheimer's and Dementia</i> , 2020, 16, 292-304.	0.4	29
39	The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer's disease. <i>Immunology and Cell Biology</i> , 2020, 98, 28-41.	1.0	231
40	An immune-cell signature marks the brain in Alzheimer's disease. <i>Nature</i> , 2020, 577, 322-323.	13.7	21
41	In vivo characterization of functional states of cortical microglia during peripheral inflammation. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 243-255.	2.0	38
42	Soluble A $\beta$ oligomers and protofibrils induce NLRP3 inflammasome activation in microglia. <i>Journal of Neurochemistry</i> , 2020, 155, 650-661.	2.1	91
43	Microglia in Alzheimer's disease: Local heroes!. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	9
44	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2020, 16, 1504-1514.	0.4	35
45	Multimodal MRI analysis of basal forebrain structure and function across the Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> , 2020, 28, 102495.	1.4	17
46	Feasibility of mobile app-based assessment of memory functions: Insights from a citizen science study. <i>Alzheimer's and Dementia</i> , 2020, 16, e039149.	0.4	1
47	Innate immune activation of the NLRP3 inflammasome pathway drives tau pathology. <i>Alzheimer's and Dementia</i> , 2020, 16, e039815.	0.4	0
48	Cognitive and biological characteristics of stage 2 of AD in the clinical multicenter DELCODE Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e040265.	0.4	0
49	NLRP3 inflammasome activation regulates microglial migration. <i>Alzheimer's and Dementia</i> , 2020, 16, e040946.	0.4	0
50	Hippocampal volumetric variability is associated with memory in subjective cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e043527.	0.4	0
51	Overview of immune system in AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e044146.	0.4	0
52	Decreased cortical thickness in individuals with subjective cognitive decline with and without CSF $\beta$ -amyloid pathology: Data from the DELCODE Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044741.	0.4	1
53	Awareness of cognitive decline and CSF biomarkers in memory clinic patients: Results from the DELCODE study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044744.	0.4	0
54	The effects of Mediterranean diet on memory and Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2020, 16, e045349.	0.4	0

#	ARTICLE	IF	CITATIONS
55	The Entorhinal Cortex Atrophy Score Is Diagnostic and Prognostic in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 99-108.	1.2	10
56	Enduring Changes in Neuronal Function upon Systemic Inflammation Are NLRP3 Inflammasome Dependent. <i>Journal of Neuroscience</i> , 2020, 40, 5480-5494.	1.7	36
57	Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 69.	3.0	367
58	T cells in Alzheimer's disease: space invaders. <i>Lancet Neurology</i> , The, 2020, 19, 285-287.	4.9	10
59	$\beta^2$ -Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia. <i>Cell Reports</i> , 2020, 30, 3743-3754.e6.	2.9	109
60	Neuroimmune Connections in Aging and Neurodegenerative Diseases. <i>Trends in Immunology</i> , 2020, 41, 300-312.	2.9	111
61	Do infections have a role in the pathogenesis of Alzheimer disease?. <i>Nature Reviews Neurology</i> , 2020, 16, 193-197.	4.9	96
62	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2020, 139, 1025-1044.	3.9	40
63	Minor neuropsychological deficits in patients with subjective cognitive decline. <i>Neurology</i> , 2020, 95, e1134-e1143.	1.5	58
64	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. <i>Nature Neuroscience</i> , 2019, 22, 1258-1268.	7.1	48
65	Systemic inflammation impairs microglial $\text{A}\beta^2$ clearance through NLRP3 inflammasome. <i>EMBO Journal</i> , 2019, 38, e101064.	3.5	226
66	Norepinephrine as a modulator of microglial dynamics. <i>Nature Neuroscience</i> , 2019, 22, 1745-1746.	7.1	7
67	Inflammasome-mediated innate immunity in Alzheimer's disease. <i>FASEB Journal</i> , 2019, 33, 13075-13084.	0.2	55
68	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 74.	3.0	28
69	Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimer's Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 455-465.	1.2	15
70	Higher CSF Tau Levels Are Related to Hippocampal Hyperactivity and Object Mnemonic Discrimination in Older Adults. <i>Journal of Neuroscience</i> , 2019, 39, 8788-8797.	1.7	64
71	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 8.	3.0	23
72	CNS-Specific Synthesis of Interleukin 23 Induces a Progressive Cerebellar Ataxia and the Accumulation of Both T and B Cells in the Brain: Characterization of a Novel Transgenic Mouse Model. <i>Molecular Neurobiology</i> , 2019, 56, 7977-7993.	1.9	17

#	ARTICLE	IF	CITATIONS
73	Dysregulation of TLR5 and TAM Ligands in the Alzheimer's Brain as Contributors to Disease Progression. <i>Molecular Neurobiology</i> , 2019, 56, 6539-6550.	1.9	31
74	NLRP3 inflammasome activation drives tau pathology. <i>Nature</i> , 2019, 575, 669-673.	13.7	782
75	Microglia take centre stage in neurodegenerative disease. <i>Nature Reviews Immunology</i> , 2019, 19, 79-80.	10.6	41
76	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies. <i>Alzheimer's and Dementia</i> , 2019, 15, 185-193.	0.4	28
77	Microglia: You'll Never Walk Alone!. <i>Immunity</i> , 2018, 48, 195-197.	6.6	6
78	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. <i>Brain</i> , 2018, 141, 1186-1200.	3.7	83
79	The ERICA Score: An MR Imaging-based Visual Scoring System for the Assessment of Entorhinal Cortex Atrophy in Alzheimer Disease. <i>Radiology</i> , 2018, 288, 226-333.	3.6	33
80	Doublecortin expression in CD8+ T cells and microglia at sites of amyloid plaques: A potential role in shaping plaque pathology?. <i>Alzheimer's and Dementia</i> , 2018, 14, 1022-1037.	0.4	36
81	Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 15.	3.0	131
82	Microglia modulation through external vagus nerve stimulation in a murine model of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2018, 146, 76-85.	2.1	65
83	Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 25.	3.0	74
84	IL-17A Promotes Granulocyte Infiltration, Myelin Loss, Microglia Activation, and Behavioral Deficits During Cuprizone-Induced Demyelination. <i>Molecular Neurobiology</i> , 2018, 55, 946-957.	1.9	44
85	Innate Immunity and Neurodegeneration. <i>Annual Review of Medicine</i> , 2018, 69, 437-449.	5.0	221
86	Variability and temporal dynamics of novel object recognition in aging male C57BL/6 mice. <i>Behavioural Processes</i> , 2018, 157, 711-716.	0.5	17
87	P1-379: CORTICAL THINNING IN SUBJECTIVE COGNITIVE DECLINE WITH AND WITHOUT AD PATHOLOGY: DATA FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P443.	0.4	0
88	P3-327: NEUROPSYCHIATRIC SYMPTOMS IN AT-RISK GROUPS FOR AD DEMENTIA AND THEIR RELATION TO AD BIOMARKERS: DATA FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1206.	0.4	0
89	P2-434: EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. <i>Alzheimer's and Dementia</i> , 2018, 14, P879.	0.4	0
90	IC-084: EFFECTS OF AGE AND CSF MEASURES OF TAU ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. <i>Alzheimer's and Dementia</i> , 2018, 14, P72.	0.4	0

#	ARTICLE	IF	CITATIONS
91	P1â€028: OCCUPATIONAL COGNITIVE REQUIREMENTS ARE AN IMPORTANT PROXY MEASURE OF COGNITIVE RESERVE: EVIDENCE FROM THE AGECODE AND DELCODE STUDIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P276.	0.4	0
92	P3â€366: MULTICENTER RESTING STATE FUNCTIONAL CONNECTIVITY IN PRODROMAL AND DEMENTIA STAGES OF ALZHEIMER'S DISEASE: RESULTS FROM THE DZNE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1228.	0.4	0
93	P3â€591: A GERMAN VERSION OF THE LIFETIME OF EXPERIENCES QUESTIONNAIRE (LEQ) TO MEASURE COGNITIVE RESERVE: VALIDATION RESULTS FROM THE DELCODE STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1352.	0.4	8
94	F4â€07â€03: RELATIONSHIP BETWEEN LOCUS COERULEUS MRI CONTRAST, COGNITION AND CSF BIOMARKERS IN AGING AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1393.	0.4	0
95	F1â€04â€02: ASSOCIATION BETWEEN NEURAL NOVELTY RESPONSES AND CSF BIOMARKERS OF ALZHEIMER'S DISEASE: ANATOMICAL SPECIFICITY AND DEPENDENCE ON ATROPHY. <i>Alzheimer's and Dementia</i> , 2018, 14, P206.	0.4	0
96	F4â€08â€04: SUBJECTIVE COGNITIVE DECLINE, AS MEASURED WITH A STRUCTURED INTERVIEW, IS RELATED TO AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1396.	0.4	0
97	F1â€04â€03: EFFECTS OF AGE AND TAU MEASURED IN CSF ON MNEMONIC DISCRIMINATION OF OBJECTS AND SCENES IN MEDIAL TEMPORAL LOBE PATHWAYS. <i>Alzheimer's and Dementia</i> , 2018, 14, P207.	0.4	0
98	P4â€068: LEVELS OF THE ASTROCYTEâ€DERIVED PROTEINS GFAP AND S100B IN THE CEREBROSPINAL FLUID OF HEALTHY INDIVIDUALS AND ALZHEIMER'S DISEASE PATIENTS AT DIFFERENT DISEASE STAGES. <i>Alzheimer's and Dementia</i> , 2018, 14, P1458.	0.4	1
99	Inflammasome signalling in brain function and neurodegenerative disease. <i>Nature Reviews Neuroscience</i> , 2018, 19, 610-621.	4.9	514
100	Cannabinoid 1 Receptor Signaling on Hippocampal GABAergic Neurons Influences Microglial Activity. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 295.	1.4	26
101	Transcriptome analysis of alcohol-treated microglia reveals downregulation of beta amyloid phagocytosis. <i>Journal of Neuroinflammation</i> , 2018, 15, 141.	3.1	34
102	A novel CHCHD10 mutation implicates a Mia40â€dependent mitochondrial import deficit in ALS. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	43
103	Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APP <sup>swe</sup> /PS1 <sup>dE9</sup> Mouse Model of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 235.	1.4	72
104	The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (A $\beta$ ) species on long-term potentiation (LTP). <i>Neuropharmacology</i> , 2018, 140, 184-192.	2.0	22
105	Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 9002-9007.	3.3	41
106	Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 801-813.	1.2	19
107	Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2018, 17, 681-688.	4.9	51
108	Intramembranous processing by Î³â€secretase regulates reverse signaling of ephrinâ€B2 in migration of microglia. <i>Glia</i> , 2017, 65, 1103-1118.	2.5	13



#	ARTICLE	IF	CITATIONS
109	<i>tbk1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017, 38, 297-309.	1.1	87
110	Inflammasome activation and innate immunity in <i>A<math>\beta</math></i> Alzheimer's disease. <i>Brain Pathology</i> , 2017, 27, 220-222.	2.1	119
111	Activation of the <i>NLRP3</i> inflammasome in microglia: the role of ceramide. <i>Journal of Neurochemistry</i> , 2017, 143, 534-550.	2.1	101
112	A guiding map for inflammation. <i>Nature Immunology</i> , 2017, 18, 826-831.	7.0	506
113	Proteome profiling of s-nitrosylated synaptosomal proteins by isobaric mass tags. <i>Journal of Neuroscience Methods</i> , 2017, 291, 95-100.	1.3	5
114	[P2 $\alpha$ 074]: MODELING OF HIDDEN CAUSES FOR DYNAMIC CHANGES IN STRUCTURAL INTEGRITY AND COGNITION IN SUBJECTIVE COGNITIVE DECLINE: A DELCODE PROJECT. <i>Alzheimer's and Dementia</i> , 2017, 13, P634.	0.4	0
115	Danger-associated molecular patterns in Alzheimer's disease. <i>Journal of Leukocyte Biology</i> , 2017, 101, 87-98.	1.5	158
116	United Again: STING and the Police. <i>Neuron</i> , 2017, 96, 1207-1208.	3.8	1
117	Microglia-derived ASC specks cross-seed amyloid- $\beta^2$ in Alzheimer's disease. <i>Nature</i> , 2017, 552, 355-361.	13.7	664
118	Targeting Neuroinflammation to Treat Alzheimer's Disease. <i>CNS Drugs</i> , 2017, 31, 1057-1082.	2.7	182
119	[P3 $\alpha$ 164]: FUNCTIONAL CHARACTERIZATION OF A RARE GENETIC VARIANT IN PHOSPHOLIPASE C $\beta$ 2 WHICH IS ASSOCIATED WITH A BENEFICIAL EFFECT ON THE PROGRESSION OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P997.	0.4	0
120	[P2 $\alpha$ 088]: CHRONIC AND ACUTE SYSTEMIC INFLAMMATION AND LONG-TERM COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P640.	0.4	2
121	Microglia in Alzheimer's disease. <i>Journal of Clinical Investigation</i> , 2017, 127, 3240-3249.	3.9	622
122	<i>sTREM2</i> cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016, 8, 466-476.	3.3	392
123	Thoughts on Obesity and Brain Glucose. <i>Cell</i> , 2016, 165, 773-775.	13.5	5
124	Early Changes in Hippocampal Neurogenesis in Transgenic Mouse Models for Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016, 53, 5796-5806.	1.9	71
125	Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. <i>Science Translational Medicine</i> , 2016, 8, 333ra50.	5.8	271
126	Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly. <i>Current Alzheimer Research</i> , 2016, 13, 370-380.	0.7	72



#	ARTICLE	IF	CITATIONS
127	Translocator protein and new targets for neuroinflammation. <i>Clinical and Translational Imaging</i> , 2015, 3, 391-402.	1.1	23
128	Effect of pioglitazone medication on the incidence of dementia. <i>Annals of Neurology</i> , 2015, 78, 284-294.	2.8	153
129	Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0132227.	1.1	55
130	Reduction of microbleeds by immunosuppression in a patient with A $\beta$ -related vascular inflammation. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e165.	3.1	9
131	Cortical Thinning in Individuals with Subjective Memory Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 139-146.	1.2	66
132	Innate immunity in Alzheimer's disease. <i>Nature Immunology</i> , 2015, 16, 229-236.	7.0	619
133	Neuroinflammation in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2015, 14, 388-405.	4.9	4,129
134	PLD3 in non-familial Alzheimer's disease. <i>Nature</i> , 2015, 520, E3-E5.	13.7	58
135	$\beta$ -Secretase processing of APP inhibits neuronal activity in the hippocampus. <i>Nature</i> , 2015, 526, 443-447.	13.7	308
136	A distinct clinical phenotype in a German kindred with motor neuron disease carrying aCHCHD10mutation. <i>Brain</i> , 2015, 138, e376-e376.	3.7	42
137	Pan-PPAR Modulation Effectively Protects APP/PS1 Mice from Amyloid Deposition and Cognitive Deficits. <i>Molecular Neurobiology</i> , 2015, 51, 661-671.	1.9	35
138	CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model. <i>Journal of Clinical Investigation</i> , 2015, 125, 365-378.	3.9	106
139	SUCLG2 identified as both a determinant of CSF A $\beta$ 1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 6644-6658.	1.4	45
140	Ear2 Deletion Causes Early Memory and Learning Deficits in APP/PS1 Mice. <i>Journal of Neuroscience</i> , 2014, 34, 8845-8854.	1.7	54
141	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , 2014, 6, 243ra86.	5.8	600
142	Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer's Disease: a Comparative Overview. <i>Molecular Neurobiology</i> , 2014, 50, 534-544.	1.9	349
143	Long-term cerebral consequences of sepsis. <i>Lancet Neurology</i> , The, 2014, 13, 630-636.	4.9	273
144	IL-17A promotes myelin loss and inflammatory response during Cuprizone-induced demyelination. <i>Journal of Neuroimmunology</i> , 2014, 275, 110.	1.1	1

#	ARTICLE	IF	CITATIONS
145	Sepsis-associated encephalopathy versus sepsis-induced encephalopathy—Authors' reply. <i>Lancet Neurology</i> , 2014, 13, 968-969.	4.9	9
146	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e13-2657.e19.	1.5	34
147	Innate immune activation in neurodegenerative disease. <i>Nature Reviews Immunology</i> , 2014, 14, 463-477.	10.6	1,053
148	Truncated and modified amyloid-beta species. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 28.	3.0	233
149	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2014, 128, 397-410.	3.9	93
150	Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia. <i>Nature Genetics</i> , 2014, 46, 901-904.	9.4	104
151	ADO: A disease ontology representing the domain knowledge specific to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 238-246.	0.4	77
152	Gray matter atrophy pattern in elderly with subjective memory impairment. <i>Alzheimer's and Dementia</i> , 2014, 10, 99-108.	0.4	129
153	Selective Loss of Noradrenaline Exacerbates Early Cognitive Dysfunction and Synaptic Deficits in APP/PS1 Mice. <i>Biological Psychiatry</i> , 2013, 73, 454-463.	0.7	95
154	Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 21.	3.0	124
155	Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 351-354.	1.5	52
156	NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. <i>Nature</i> , 2013, 493, 674-678.	13.7	2,063
157	A Pan-European Study of the C9orf72 Repeat Associated with FTL: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. <i>Human Mutation</i> , 2013, 34, 363-373.	1.1	247
158	Long-term neuromuscular sequelae of critical illness. <i>Journal of Neurology</i> , 2013, 260, 151-157.	1.8	45
159	Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 62-69.	0.9	341
160	The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 67-77.	1.2	53
161	Clinical Symptoms and Risk Factors in Cerebral Microangiopathy Patients. <i>PLoS ONE</i> , 2013, 8, e53455.	1.1	44
162	CNS-Targeted Production of IL-17A Induces Glial Activation, Microvascular Pathology and Enhances the Neuroinflammatory Response to Systemic Endotoxemia. <i>PLoS ONE</i> , 2013, 8, e57307.	1.1	60

#	ARTICLE	IF	CITATIONS
163	TLR2 Is a Primary Receptor for Alzheimer's Amyloid $\beta$ Peptide To Trigger Neuroinflammatory Activation. <i>Journal of Immunology</i> , 2012, 188, 1098-1107.	0.4	346
164	PPAR $\beta$ /RXR $\alpha$ -Induced and CD36-Mediated Microglial Amyloid- $\beta$ Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice. <i>Journal of Neuroscience</i> , 2012, 32, 17321-17331.	1.7	277
165	Mrp14 Deficiency Ameliorates Amyloid $\beta$ Burden by Increasing Microglial Phagocytosis and Modulation of Amyloid Precursor Protein Processing. <i>Journal of Neuroscience</i> , 2012, 32, 17824-17829.	1.7	60
166	A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2012, 7, e37885.	1.1	125
167	Glial cells in (patho)physiology. <i>Journal of Neurochemistry</i> , 2012, 121, 4-27.	2.1	460
168	Nitric Oxide Decreases the Enzymatic Activity of Insulin Degrading Enzyme in APP/PS1 Mice. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 165-172.	2.1	24
169	Microglial activation in a neuroinflammatory animal model of schizophrenia – a pilot study. <i>Schizophrenia Research</i> , 2011, 131, 96-100.	1.1	158
170	Opposing Roles for CXCR3 Signaling in Central Nervous System Versus Ocular Inflammation Mediated by the Astrocyte-Targeted Production of IL-12. <i>American Journal of Pathology</i> , 2011, 179, 2346-2359.	1.9	10
171	Nitration of Tyrosine 10 Critically Enhances Amyloid $\beta$ Aggregation and Plaque Formation. <i>Neuron</i> , 2011, 71, 833-844.	3.8	259
172	Restraint stress increases neuroinflammation independently of amyloid $\beta$ levels in amyloid precursor protein/PS1 transgenic mice. <i>Journal of Neurochemistry</i> , 2011, 116, 43-52.	2.1	16
173	Neuroinflammatory and behavioural changes in the Atp7B mutant mouse model of Wilson's disease. <i>Journal of Neurochemistry</i> , 2011, 118, 105-112.	2.1	41
174	Extracellular phosphorylation of the amyloid $\beta$ -peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. <i>EMBO Journal</i> , 2011, 30, 2255-2265.	3.5	160
175	Impact and Therapeutic Potential of PPARs in Alzheimers Disease. <i>Current Neuropharmacology</i> , 2011, 9, 643-650.	1.4	99
176	Critical Role of Astroglial Apolipoprotein E and Liver X Receptor- $\alpha$ Expression for Microglial A $\beta$ Phagocytosis. <i>Journal of Neuroscience</i> , 2011, 31, 7049-7059.	1.7	163
177	Distinct and Non-Redundant Roles of Microglia and Myeloid Subsets in Mouse Models of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2011, 31, 11159-11171.	1.7	286
178	Neuroinflammatory processes in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 919-947.	1.4	380
179	Neuroglia in neurodegeneration. <i>Brain Research Reviews</i> , 2010, 63, 189-211.	9.1	247
180	The other brain. <i>Journal of Clinical Investigation</i> , 2010, 120, 1789-1789.	3.9	7

#	ARTICLE	IF	CITATIONS
181	Statins Promote the Degradation of Extracellular Amyloid $\beta$ -Peptide by Microglia via Stimulation of Exosome-associated Insulin-degrading Enzyme (IDE) Secretion. <i>Journal of Biological Chemistry</i> , 2010, 285, 37405-37414.	1.6	176
182	Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 6058-6063.	3.3	408
183	Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. <i>Neurochemistry International</i> , 2010, 57, 375-382.	1.9	116
184	<i>iNOS</i> Gene Deficiency Protects from Sepsis-Induced Long-Term Cognitive Deficits. <i>Journal of Neuroscience</i> , 2009, 29, 14177-14184.	1.7	125
185	PPAR $\gamma$ and RXR $\gamma$ ligands act synergistically as potent antineoplastic agents <i>in vitro</i> and <i>in vivo</i> glioma models. <i>Journal of Neurochemistry</i> , 2009, 109, 1779-1790.	2.1	55
186	$\beta$ -Secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits $A\beta$ generation. <i>Journal of Neurochemistry</i> , 2009, 111, 1369-1382.	2.1	57
187	Noradrenergic denervation facilitates the release of acetylcholine and serotonin in the hippocampus: Towards a mechanism underlying upregulations described in MCI patients. <i>Experimental Neurology</i> , 2009, 217, 237-239.	2.0	1
188	PPAR $\gamma$ Agonists as Therapeutics for the Treatment of Alzheimer's Disease. <i>Neurotherapeutics</i> , 2008, 5, 481-489.	2.1	254
189	Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. <i>Journal of Neuroinflammation</i> , 2008, 5, 38.	3.1	223
190	The Role of Peroxisome Proliferator-Activated Receptor- $\gamma$ (PPAR $\gamma$ ) in Alzheimer's Disease. <i>CNS Drugs</i> , 2008, 22, 1-14.	2.7	155
191	Loss of $\beta$ -Secretase Function Impairs Endocytosis of Lipoprotein Particles and Membrane Cholesterol Homeostasis. <i>Journal of Neuroscience</i> , 2008, 28, 12097-12106.	1.7	62
192	Noradrenaline deficiency in brain increases $\beta$ -amyloid plaque burden in an animal model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2007, 28, 1206-1214.	1.5	168
193	Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model. <i>Experimental Neurology</i> , 2007, 204, 733-740.	2.0	206
194	Imaging-Guided Gene Therapy of Experimental Gliomas. <i>Cancer Research</i> , 2007, 67, 1706-1715.	0.4	62
195	Drug Insight: effects mediated by peroxisome proliferator-activated receptor- $\gamma$ in CNS disorders. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 496-504.	2.7	86
196	Switching on the Lights for Gene Therapy. <i>PLoS ONE</i> , 2007, 2, e528.	1.1	24
197	Inflammatory processes in Alzheimer's disease. <i>Journal of Neuroimmunology</i> , 2007, 184, 69-91.	1.1	664
198	Reduction of Amyloid Angiopathy and $A\beta$ Plaque Burden after Enriched Housing in TgCRND8 Mice. <i>American Journal of Pathology</i> , 2006, 169, 544-552.	1.9	81

#	ARTICLE	IF	CITATIONS
199	Disease-Modifying Therapies in Alzheimer's Disease. <i>Drugs</i> , 2006, 66, 2075-2093.	4.9	90
200	PPAR $\delta$ as a therapeutic target in central nervous system diseases. <i>Neurochemistry International</i> , 2006, 49, 136-144.	1.9	97
201	Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. <i>International Journal of Developmental Neuroscience</i> , 2006, 24, 167-176.	0.7	375
202	Inflammation in Alzheimer's disease. <i>Clinical Neuroscience Research</i> , 2006, 6, 247-260.	0.8	23
203	Inhibition of in Vivo Glioma Growth and Invasion by Peroxisome Proliferator-Activated Receptor $\delta$ Agonist Treatment. <i>Molecular Pharmacology</i> , 2006, 70, 1524-1533.	1.0	98
204	Nonsteroidal anti-inflammatory drugs repress $\beta$ -secretase gene promoter activity by the activation of PPAR $\alpha$ . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 443-448.	3.3	365
205	GGA1 Is Expressed in the Human Brain and Affects the Generation of Amyloid $\beta$ -Peptide. <i>Journal of Neuroscience</i> , 2006, 26, 12838-12846.	1.7	82
206	Locus Ceruleus Degeneration Promotes Alzheimer Pathogenesis in Amyloid Precursor Protein 23 Transgenic Mice. <i>Journal of Neuroscience</i> , 2006, 26, 1343-1354.	1.7	268
207	The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice. <i>Journal of Neuroscience</i> , 2005, 25, 7805-7812.	1.7	196
208	Proinflammatory Stimulation and Pioglitazone Treatment Regulate Peroxisome Proliferator-Activated Receptor $\delta$ Levels in Peripheral Blood Mononuclear Cells from Healthy Controls and Multiple Sclerosis Patients. <i>Journal of Immunology</i> , 2005, 175, 4948-4955.	0.4	103
209	Inhibition of Glycosphingolipid Biosynthesis Reduces Secretion of the $\beta$ -Amyloid Precursor Protein and Amyloid $\beta$ -Peptide. <i>Journal of Biological Chemistry</i> , 2005, 280, 28110-28117.	1.6	115
210	Acute treatment with the PPAR $\delta$ agonist pioglitazone and ibuprofen reduces glial inflammation and $\beta$ -42 levels in APPV717I transgenic mice. <i>Brain</i> , 2005, 128, 1442-1453.	3.7	522
211	The Nonthiazolidinedione Tyrosine-Based Peroxisome Proliferator-Activated Receptor $\delta$ Ligand GW7845 Induces Apoptosis and Limits Migration and Invasion of Rat and Human Glioma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 806-813.	1.3	27
212	Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. <i>Journal of Chemical Neuroanatomy</i> , 2005, 30, 144-157.	1.0	387
213	Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with $\beta$ -galactosidase induction and block of NF $\kappa$ B and iNOS activation. <i>Journal of Neurochemistry</i> , 2004, 88, 494-501.	2.1	347
214	Anti-inflammatory and antiproliferative actions of PPAR $\delta$ agonists on T lymphocytes derived from MS patients. <i>Journal of Leukocyte Biology</i> , 2004, 75, 478-485.	1.5	85
215	Antineoplastic effects of peroxisome proliferator-activated receptor $\delta$ agonists. <i>Lancet Oncology</i> , 2004, 5, 419-429.	5.1	413
216	Intrinsic regulation of brain inflammatory responses. <i>Cellular and Molecular Neurobiology</i> , 2003, 23, 625-635.	1.7	64

#	ARTICLE	IF	CITATIONS
217	Interleukin-1 $\beta$ and lipopolysaccharide decrease soluble guanylyl cyclase in brain cells: NO-independent destabilization of protein and NO-dependent decrease of mRNA. <i>Journal of Neuroimmunology</i> , 2003, 144, 80-90.	1.1	23
218	Noradrenergic depletion increases inflammatory responses in brain: effects on I $\kappa$ B and HSP70 expression. <i>Journal of Neurochemistry</i> , 2003, 85, 387-398.	2.1	134
219	Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPAR $\gamma$ ) in murine primary astrocytes and neurons. <i>Journal of Neurochemistry</i> , 2003, 86, 907-916.	2.1	47
220	IFN- $\gamma$ 1a (Rebif $\text{\textcircled{R}}$ ) Modifies the Expression of Microfilament-Associated Cell-Cell Contacts in C6 Glioma Cells. <i>Journal of Interferon and Cytokine Research</i> , 2003, 23, 83-89.	0.5	2
221	Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor- $\gamma$ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of $\beta$ -Secretase. <i>Journal of Neuroscience</i> , 2003, 23, 9796-9804.	1.7	347
222	Norepinephrine Increases I $\kappa$ B $\alpha$ Expression in Astrocytes. <i>Journal of Biological Chemistry</i> , 2002, 277, 29662-29668.	1.6	70
223	$\beta$ -Amyloid Peptides Decrease Soluble Guanylyl Cyclase Expression in Astroglial Cells. <i>Neurobiology of Disease</i> , 2002, 10, 139-149.	2.1	43
224	Noradrenergic regulation of inflammatory gene expression in brain. <i>Neurochemistry International</i> , 2002, 41, 357-365.	1.9	199
225	Noradrenergic Depletion Potentiates $\beta$ -Amyloid-Induced Cortical Inflammation: Implications for Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2002, 22, 2434-2442.	1.7	231
226	Suppressive effects of ansamycins on inducible nitric oxide synthase expression and the development of experimental autoimmune encephalomyelitis. <i>Journal of Neuroscience Research</i> , 2002, 67, 461-470.	1.3	44
227	Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPAR $\gamma$ . <i>Journal of Neurochemistry</i> , 2002, 81, 1052-1060.	2.1	119
228	Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2001, 22, 937-944.	1.5	167
229	The heat shock response reduces myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in mice. <i>Journal of Neurochemistry</i> , 2001, 77, 568-579.	2.1	32
230	Role for peroxisome proliferator-activated receptor- $\gamma$ in Alzheimer's disease. <i>Annals of Neurology</i> , 2001, 49, 276-276.	2.8	53
231	Expression and function of inducible nitric oxide synthase in neurons. <i>Journal of Neuroimmunology</i> , 2001, 114, 8-18.	1.1	214
232	Neuronal and Glial Coexpression of Argininosuccinate Synthetase and Inducible Nitric Oxide Synthase in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 906-916.	0.9	134
233	The Heat Shock Response Inhibits NF- $\kappa$ B Activation, Nitric Oxide Synthase Type 2 Expression, and Macrophage/Microglial Activation in Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 800-811.	2.4	67
234	Peroxisome Proliferator-Activated Receptor- $\gamma$ Ligands Reduce Neuronal Inducible Nitric Oxide Synthase Expression and Cell Death <i>In Vivo</i> . <i>Journal of Neuroscience</i> , 2000, 20, 6862-6867.	1.7	255

#	ARTICLE	IF	CITATIONS
235	Temporal, regional, and cell-specific changes of iNOS expression after intrastriatal microinjection of interferon gamma and bacterial lipopolysaccharide. <i>Journal of Chemical Neuroanatomy</i> , 2000, 18, 167-179.	1.0	27
236	Induction of Argininosuccinate Synthetase in Rat Brain Glial Cells after Striatal Microinjection of Immunostimulants. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1999, 19, 898-907.	2.4	27
237	Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. <i>Journal of Neuroimmunology</i> , 1999, 100, 156-168.	1.1	146
238	Selective Potentiation of Drug Cytotoxicity by NSAID in Human Glioma Cells: The Role of COX-1 and MRP. <i>Biochemical and Biophysical Research Communications</i> , 1999, 259, 600-605.	1.0	55
239	Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. <i>Cell Death and Differentiation</i> , 1998, 5, 847-857.	5.0	93
240	Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF- $\beta$ 2 dexamethasone, and p53 gene transfer. <i>Oncogene</i> , 1998, 17, 2323-2332.	2.6	30
241	Induction of Nitric Oxide Synthase and Nitric Oxide-Mediated Apoptosis in Neuronal PC12 Cells After Stimulation with Tumor Necrosis Factor- $\alpha$ /Lipopolysaccharide. <i>Journal of Neurochemistry</i> , 1998, 71, 88-94.	2.1	186
242	Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. <i>Synapse</i> , 1997, 26, 381-391.	0.6	34